Children’s Medical Center has been granted a patent for chimeric VEGF-binding proteins and nucleic acids to treat angiogenic diseases. The method involves administering a vector encoding a specific protein sequence. GlobalData’s report on Children’s Medical Center gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Children's Medical Center, was a key innovation area identified from patents. Children's Medical Center's grant share as of May 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for chimeric vegf-binding protein treatment method
A recently granted patent (Publication Number: US11999775B2) discloses a method for treating angiogenic diseases or disorders by administering a vector containing a polynucleotide encoding a chimeric VEGF-binding protein with a specific amino acid sequence. The vector can be an expression vector compatible with various host cells like mammalian, insect, yeast, bacterial, or plant cells, or it can be a viral vector such as an adeno-associated virus (AAV) or lentivirus vector.
Furthermore, the patent claims cover the treatment of specific conditions such as cancer (including lung cancer), age-related macular degeneration, wet macular degeneration, diabetic retinopathy, abnormal blood vessel growth in the skin, hemangioma, and endometriosis. Additionally, the method also includes reducing blood vessel formation in tumors, particularly lung cancer tumors, through the administration of the vector encoding the chimeric VEGF-binding protein. The administration can be done intratumorally or peritumorally, offering a targeted approach for addressing angiogenesis in tumors.
To know more about GlobalData’s detailed insights on Children's Medical Center, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
